News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Reinforce Baxter International, Inc. (BAX)'s Commitment to Making GAMMAGARD LIQUID Therapy More Convenient


3/16/2009 8:48:56 AM

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) announced data supporting further progress in efforts to make antibody therapy more convenient for patients with primary immunodeficiency (PID), including ways to give patients more options of where, how often and when they receive treatment. The data were presented in three posters at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, D.C., on Saturday, March 14.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES